Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bosakitug
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Aclaris Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Aclaris Announces Global License Agreement Adding Biologics Assets to Pipeline
Details : Aclaris gains worldwide rights (excluding Greater China) to BSI-045B, a novel anti-TSLP monoclonal antibody, and BSI-502, a novel bispecific antibody that is directed against both TSLP and IL4R.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
November 18, 2024
Lead Product(s) : Bosakitug
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Aclaris Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : OBI-992
Therapeutic Area : Oncology
Study Phase : IND Enabling
Recipient : OBI Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Biosion's Partner OBI Pharma Announces FDA Clearance for OBI-992 Phase 1/2 Study
Details : OBI-992 is a novel antibody drug conjugate (ADC) cancer therapy targeting TROP2. It is being evaluated for the treatment of non-small cell lung cancer, small cell lung cancer & gastric cancer.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
August 01, 2024
Lead Product(s) : OBI-992
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : OBI Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bosakitug,Dupilumab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in Atopic Dermatitis (ADAMANT)
Details : BSI-045B is a high-affinity, humanized monoclonal antibody, targeting thymic stromal lymphopoietin (TSLP), a cytokine that is implicated in the pathogenesis of atopic dermatitis, asthma and other eosinophilic and Th2 immune-related diseases.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
July 31, 2023
Lead Product(s) : Bosakitug,Dupilumab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BSI-045B
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
July 06, 2023
Lead Product(s) : BSI-045B
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CDX-585
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Celldex Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CDX-585 is a dual targeting PD-1/ILT4 bispecific antibody from Celldex’s bispecific antibody platform, being developed for the treatment of solid tumors either as monotherapy or in combination with other oncologic treatments.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 31, 2023
Lead Product(s) : CDX-585
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Celldex Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bosakitug
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biosion Initiates Phase II Clinical Trial of BSI-045B in Atopic Dermatitis
Details : BSI-045B is a high-affinity, humanized monoclonal antibody, targeting thymic stromal lymphopoietin (TSLP), a cytokine that is implicated in the pathogenesis of atopic dermatitis, asthma and other eosinophilic and Th2 immune-related diseases.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 04, 2023
Lead Product(s) : Bosakitug
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biosion Announces Research Collaboration with ImmunoGen to Create Novel Antibody-Drug Conjugates
Details : Biosion will leverage its proprietary SynTracer® high-throughput endocytosis platform to generate highly selective antibodies to targets allocated by each company and ImmunoGen will provide their proprietary linker-payload technology to create novel Ant...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 13, 2022
Lead Product(s) : BSI0-4702
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : OBI Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The license agreement enables OBI Pharma to conduct further preclinical and clinical development, registration, and commercialization of BSI04702 as an Antibody Drug Conjugate and other derivative products.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
December 13, 2021
Lead Product(s) : BSI0-4702
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : OBI Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : BSI-045B
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Southern Star Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Tolerability of BSI-045B in Healthy Adult Subjects and Patients With Atopic Dermatitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
November 10, 2021
Lead Product(s) : BSI-045B
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Southern Star Research
Deal Size : Inapplicable
Deal Type : Inapplicable